You are previewing The Funding of Biopharmaceutical Research and Development.
O'Reilly logo
The Funding of Biopharmaceutical Research and Development

Book Description

The funding of biopharmaceutical research and development provides a comprehensive critical review of the funding of research and development (R&D) in the human biopharmaceutical market sector. It addresses both private and public funding sources available in the US and internationally. The biopharmaceutical market is among the most research-intensive market sectors globally. Clinical researchers face a multitude of public and private funding options with respect to bringing their idea or innovation to market. These funding options are continually changing and complex, and are expected to decrease in the near future. A lack of understanding of the scale, scope, and inner workings of the funding aspects of R&D can, at times, act as a barrier for all involved, and can slow down or even eliminate the R&D process. The book lessens these barriers by describing the theoretical underpinnings, present practice, and trends in R&D funding in this market sector, both in the US and internationally. This includes a review and discussion of public-private partnership activity and their inner-workings, noting the complementary relationship between public and private funding. The book also contains an overview of the inner-workings of strategic alliance activity, including the advantages and disadvantages for each party. It goes on to provide an outline of venture capital activity, detailing the methods by which venture capital firms raise capital and are organized, a description of the venture capital-entrepreneur arrangement, and the effects of this arrangement. The book also presents an overview of the IPO process and the various fates of firms going public.

  • Presents a comprehensive view of the funding issues of R&D in this market sector, adopting a theory-to-practice approach
  • A comprehensive and analytical review of the biopharmaceutical R&D literature and practice
  • An overview of the various and competing/complementary theories of the firm and valuation methods as they apply to biopharmaceutical R&D

Table of Contents

  1. Cover image
  2. Title page
  3. Table of Contents
  4. Copyright
  5. Dedication
  6. List of figures and tables
  7. Glossary
  8. Preface
  9. About the author
  10. Chapter 1: Introduction to the biopharmaceutical market
    1. Abstract:
    2. 1.1 Introduction
    3. 1.2 Synopsis of the development of the biopharmaceutical market sector
    4. 1.3 Global growth of research and biopharmaceuticals
    5. 1.4 Biopharmaceutical and healthcare value chain
    6. 1.5 Demand for biopharmaceuticals
    7. 1.6 Approval process
    8. 1.7 Generic medicines
    9. 1.8 Pricing of drugs
    10. 1.9 Summary
    11. 1.10 References
  11. Chapter 2: Synopsis of theories of the firm and valuation methods
    1. Abstract:
    2. 2.1 Introduction
    3. 2.2 The neoclassical perfect competition model
    4. 2.3 Industrial organization economics
    5. 2.4 Resource-based view of the firm
    6. 2.5 Innovation and entrepreneurship
    7. 2.6 Valuation
    8. 2.7 Real options
    9. 2.8 Final words on valuations
    10. 2.9 Corporate control
    11. 2.10 Summary
    12. 2.11 References
  12. Chapter 3: Innovation and the merging of the pharmaceutical and biotechnology industries
    1. Abstract:
    2. 3.1 Patents and patent protection
    3. 3.2 Standards and S-curves
    4. 3.3 Real options reasoning
    5. 3.4 Pro-innovation bias
    6. 3.5 Summary
    7. 3.6 References
  13. Chapter 4: The funding of basic research and public–private partnerships
    1. Abstract:
    2. 4.1 Introduction to research funding in the U.S.
    3. 4.2 Research funding in the European Union
    4. 4.3 Research funding in Asia
    5. 4.4 Technology transfer
    6. 4.5 Technology transfer offices
    7. 4.6 Bioclusters
    8. 4.7 Biocenters
    9. 4.8 Spill-overs and the diffusion of biopharmaceuticals
    10. 4.9 Summary
    11. 4.10 References
  14. Chapter 5: Strategic alliances
    1. Abstract:
    2. 5.1 Introduction to strategic alliances
    3. 5.2 Forms of strategic alliances
    4. 5.3 Models of the management of multiple alliances
    5. 5.4 Not all alliances are strategic
    6. 5.5 Opportunism in strategic alliances
    7. 5.6 Summary
    8. 5.7 References
  15. Chapter 6: Angel and venture capital
    1. Abstract:
    2. 6.1 Introduction to angel investors and venture capital
    3. 6.2 Venture capital staging
    4. 6.3 Venture capital history
    5. 6.4 Ownership structure
    6. 6.5 Venture capital and the entrepreneur
    7. 6.6 Venture capital around the world
    8. 6.7 Summary
    9. 6.7 References
  16. Chapter 7: The initial public offering
    1. Abstract:
    2. 7.1 An introduction to the initial public offering
    3. 7.2 A brief synopsis of the history of stock exchanges
    4. 7.3 The IPO process in the United States
    5. 7.4 IPOs around the U.S.
    6. 7.5 Research and development expenditures and financial condition
    7. 7.6 IPO performance
    8. 7.7 Venture capital involvement
    9. 7.8 IPO as exit
    10. 7.9 IPO activity around the world
    11. 7.10 Summary
    12. 7.11 References
  17. Chapter 8: Conclusion
    1. Abstract:
    2. 8.1 References
  18. Index